Pharm Section 3 Flashcards
more than ____% of americans have 1 or more types of CVD (cardiovascular disease)
20% of males and females (more than 60 million)
heart disease, tx, and prevention accounts for ____% of healthcare expenditures in the US
17%
_______ from heart disease has gone down, but the number of ________ has remained virtually the same
death; coronary events
stent
sleeve inserted into an obstructed artery that has been ballooned open by angioplasty (PCTA).
rapamycin
an imunosuppresant that prevents rejection (coats stents)
traditional risk factors for CVD
increasing age (45+ male, 55+ female)
fam hx of premature cardiac heart disease
smoking, second-hand smoke
HDL <40mg/dL
hypertension (double risk for every 20/10mmHg increase)
lack of physical activity, being overweight
diabetes/insulin resistance
newer markers for CVD
Lipoprotein a (Lp(a)) Apolipoproetin B (APOB) homocysteine hematological factors troponin Myeloperoxidase (MPO) Brain natriuretic peptide (BNP) high sensitivity C-reactive protein (hs-CRP)
BNP is used to rule out….
heart failure
C-reactive protein levels are indicative of…
inflammation. hs-CRP levels >3mg/L = high risk; 1-3 mg/L normal, <1mg/L = low risk
c-reactive protein can be lowered by
diet, exercise, statins, aspirin, alcohol
CAD spectrum of acute coronary syndromes & ST elevation
stable angina > unstable angina > NSTEMI > STEMI. ST elevation @ STEMI only.
ACS (acute coronary syndrome) treatments strategies
reperfusion or revscularization therapy including thrombolysis, PCI +/- stunting, CABG, and medical therapy. antithrombic cotherapy (ASA, UFH, LMWH, Penta., DTI, GP IIb, IIIa), ADP agonist) and acute and long-term medical therapy (Nitrates, beta blockers, ACEIs, ARBs, CCBs, Statins, APT)
antithrombic drugs include what types of drugs?
anticoagulants, antiplatelets, and thrombolytic agents
drug of choice for prevention and tx of arterial thrombosis?
anti platelet drugs. Used primarily for ACS (acute coronary syndrome) and STEMI (ST-elevation myocardial infarction)
ACS is an all-encompassing term that refers to…
Unstable angina (UA), Non-Q wave myocardial infarction, and Q-wave myocardial infarction
drug of choice for prevention and treatment of venous thromboembolism (VTE), DVT, PE in patients undergoing PCI or PTCA or for prevention of cardioembolic events in pts with a fib
anticoagulants
arterial thrombi are composed of…
mainly of platelet aggregates held together by small amounts of fibrin. Anti platelet drugs are #1 for pv/tx of arterial thrombosis, but anticoagulants also effective/can add to effect of antiplatelets
venous thrombi are composed of…
mainly of fibrin and trapped RBCs (relatively few platelets). anticoagulants are #1 for pv/tx
what are fibrinolytic agents used for?
rapid dissolution of thromboemboli, usually during MIs
clotting cascade
intrinsic and extrinsic pathways, common pathway.
vitamin K antagonists
aka warfarin. disrupt extrinsic pathway of clotting cascade during transition from Factor VII to VIIa. also disrupt @ intrinsic pathway during transition from Factor IX to IXa, @ common pathway between Factor X and Xa and prothrombin to thrombin.
oral Xa inhibitors
inhibit Factor Xa directly in common pathway
direct thrombin inhibitors
act to directly inhibit thrombin in common pathway
parenteral anticoagulant agents include
Unfractionated heparni (UFH), low-molecular-weight heparins (LMWHs), Pentasaccharide (selective Factor Xa inhibitors), Thrombin-Specific anticoagulants or direct thrombin inhibitors (DTIs), oral anticoagulants, newer oral anticoagulants (NOACs), new antithrombis for A fib, anti platelet drugs, glycoprotein IIb/IIIa inhibitors
heparin is only administered via what route?
parenteral with small gauge needle to avoid hematoma formation at injection site
heparin is derived from…?
hog mucosa or bovine lung
heparin MOA (mechanism of action)
decreases thrombin by binding to antithrombin II. forms complex, inactivates factor Xa, prevents conversion of prothrombin to thrombin (inhibits fibrinogen to fibrin).
heparin does NOT have ________ activity
fibrinolytic
effects of heparin
anticoagulation, inhibits platelet function, increases vascular permeability (all contribute to hemorrhagic effects of heparin)
antidote for bleeding related to heparin overdose
protamine sulfate
how do you test for heparin?
activated partial thromboplastin time (aPTT) or anti-Xa heparin assay (HA)
aPTT levels should remain between 1.5 and 2.5 times the normal control level
herpain-induced thrombocytopenia (HIT)
prothrombic adverse drug effect. platelet activating antibodies react against complexes of platelet factor IV and heparin. Rare, but significant mortality. Less common with LMWH. Associated with thrombosis, not bleeding.
is suspect HIT, what do you do?
immediately stop heparin tx. initiate alternative anticoagulant (i.e. argatroban, bivalirudin, fondaparinux)
heparin is available in two strengths…?
10 units/mL and 10,000 units/mL
LMWH derivatives are formed by…
cleaving standard heparin into shorter chains
benefits of LMWHs
- more effect on factor Xa
- more bioavailable with with dose-dependent plasma levels
- produce more predictable plasma heparin concentrations (can use fixed doses w.o monitoring)
- have longer half life (need fewer doses)
- decreased risk of bleeding/HIT (less effect on platelet function)
- less bone loss
protamine and LMWHs
doesn’t neutralize b/c absorbed faster than UFH, but reverses 60% of its effects
LMWH does is dependent on…?
actual body weight
1st line prevention and treatment for venous thromboembolism (VTE)?
LMWHs
LMWH agents
enoxaparin (Lovenox–inpt and outpt approved), dalteparin (Fragmin), Ardeparin (Normiflo), and Tinzaparin (Innohep)
Fondaparinux (Arixta)
antithrombotic action. inhibits single, targeted step in coagulation cascade (factor Xa). does NOT directly inhibit thrombin. Evidence suggests works as well as LMWH Lovenox and may cause fewer bleeds.
protamine and fondaparinux
protamine will not reverse its effects. must monitor factor Xa levels.
fondaparinux black box warning
warning for risk of bleeding with spinal or epidural hematoma, which could lead to long term or permanent paralysis.
fondaparinux contraindications
don’t give to patients with severe renal impairment (levels can accumulate).
thrombin specific anticoagulant/ direct thrombin inhibitors (DTIs)
cause the inhibition of thrombin independent of antithrombin. greater specificity. reduced tendency for bleeding b/c don’t directly affect platelet function.
injectable DTIs
Bivalirudin (Angiomax)
Desirudin (Iprivask)–recombinant of leech anticoagulant protein. Expensive.
Argatroban (no brand name)
oral anticoagulants (antithrombotics)
warfarin (Coumadin), newer oral anticoagulants (NOACs)
warfarin MOA
used orally. primary MOA is to interfere with the production of vitamin-K dependent clotting factors II, VII, IX, and X.
vitamin K
fat soluble vitamin. “K” derived from german word “koagulation”
clotting factor activity reduced by _____% when therapeutic doses of warfarin are given
30-50%
warfarin action @ liver
interferes with hepatic recycling of vitamin K by inhibiting reductase enzyme system that converts Vit K epoxide to Vit K. Accumulation of Vitamin K epoxide reduces effective concentration of Vit K and reduces the synthesis of coagulation factors.
vitmin K supplementation in pts taking warfarin?
usually pts educated to avoid vitamin K, but recent research shows supplementation with low dose k vitamins might reduce serious bleeding complications associated with warfarin therapy.
antidote for warfarin
vitamin K (injection or oral) can also administer: fresh frozen plasma, recombinant factor VIIa, prothrombin complex concentrates,
current vitamin K recommendations
take orally. use less.
warfarin INR (international normalized ratio)
2-3. anything =+4 shows no added benefit and increases risk of bleeding.
complications of long term anticoagulant therapy
major bleeding events like intracranial hemorrhaging. black box warning for potential fatal bleeding
warfarin original use
rat poison
warfarin and pregnancy
contraindicated for use in pregnancy
why is warfarin involved in so many drug interactions?
metabolized at the liver by P450 system. highly plasma protein bound ,but easily displaced so easy to interact with other drugs (tylenol, celebrex)
genetic testing and warfarin
CYP2C9 and VKORC1 genetic carriers face higher risk of bleeding on warfarin
NOACs
new oral anticoagulants. all have boxed warning for discontinuation and increased risk of stroke. shorter acting w. 12 hour half lives (40 hours for warfarin). includes dabigatran (Pradaxa), rivaroxaban (Zarelto), apixaban (Eliquis), and Edoxaban (Savaysa)
Dabigatran (Pradaxa)
NOAC. has an antidote: idarucizumab (Praxbind). IV injection. Expensive.
the only once-daily factor Xa inhibitor?
endoxaban (Savaysa)
black box warning for endoxaban (Savaysa)
don’t use in A fib patients with creatinine clearance < 95 mL/min. avoid using in patients with STRONG renal function.
NOACs vs warfarin
NOACs at least as effective as warfarin
NOACs have faster onset, fewer interactions, cause less bleeding
Afib pts 4x more likely to die from ______ than ______.
stroke than GI bleed.
NOACs and adherence
strict adherence is critical with NOACs because most don’t have antidotes and missing just a couple of doses increases risk for stroke (NOACs have much shorter durations than warfarin).
In what patient populations would warfarin be recommended over NOACs?
end-stage kidney disease pts, hemodialysis pts, and pts with mechanical heart valves.
Compared to warfarin, NOACs were associated with a _____% reduction in stroke or systemic embolic events and ____% inc. in GI bleeding.
19% reduction in stroke and 25% inc. in GI bleed.
NOACs and MIs/ ischemia strokes?
meta-analyses show a small, statistically insignificant reduction in stroke and MIs with NOACs
anticoagulation in afib patients after a GI bleed?
15% of pts on anticoagulant will have GI bleed, 25% of those won’t restart. Much more likely to die of stroke than GI bleed, so it’s recommended they do start back if @ high risk for stroke. Take warfarin or Eliquis over others, less chance of GI bleed. NOT PRADAXA–riskiest. Also recommended PPI in pts with upper GI bleed (benefits outweigh risks).
Some afib patients will need warfarin plus…?
an anti-platelet drug. CAUTION against triple anti-thrombotic therapy b/c inc. bleeding risk.
who is at high risk for stroke?
those with prior stroke or TIA, 75 years or older, diabetes, hypertension, etc.
what anti-thrombotic for VTE tx?
direct oral anticoagulants (DOACs) like Eliquis (apixaban) or Xarelto (rivaroxaban)
Why are Eliquix (apixaban) and Xarelto (rivaroxaban) preferred for tx of VTEs?
they don’t require pretreatment with LMWHs like dabigatran (Pradaxa) and edoxaban (Savaysa), work as well as warfarin, and have lower risk of bleeding.
what anticoagulant is recommended for pts with severe renal impairment, esp those over 75 or who are underweight?
warfarin
what anticoagulant is recommended when adherence is problematic?
warfarin. longer duration so more forgiving when doses are missed.
what anticoagulant is recommended for pts with mechanical heart valves? what kind are not recommended?
warfarin is recommended, DOACs are not (less effective with mechanical valves)
When might you see anticoagulants and LMWHs?
special cases like pregnancy, severe liver diseases, or in pts that develop clots while on oral anticoagulants
What is recommended tx for pts with clots above the knee or clots that result in PE?
tx with anticoagulant for at least three months
BOTTOM LINE for anticoagulants for afib pts?
Pts well controlled on warfarin should remain on warfarin; for all others, one of the DOACs might be a better choice.
DOACs are _______ as effective as warfarin in preventing stroke or systemic embolism in fib pts, and they appear to be _______.
at least as effective and appear to be safer.
PAIs…?
platelet aggregation inhibitors aka anti-platelet drugs.
mechanisms of action for PAIs?
COX inhibition ADP or P2Y12 inhibition GP IIb-IIIa inhibition PDE inhibition PAR-1 inhibition
COX inhibitors include…?
aspirin and NSAIDs
antiinflammatory agents inhibit what?
COX-1 (prostaglandins and thromboxane > GI protection and platelet function) and COX-2 (prostaglandins > mediate inflammation, pain, fever. All starts with arachidonic acid (beginning of pathway).
drug used for secondary prevention (second heart attack)?
aspirin (since 1974!)
how does aspirin work to inhibit platelet activation/aggregation?
acetylates COX-1, blocking thromboxane synthesis and inhibiting platelet activation/aggregation IRREVERSIBLY for the life of the platelet (usually 5-7 days, up to 10 days.
Platelets have daily turnover of about _____%?
10-15%
Durlaza
RX extended release aspirin, most feel it’s no more effective than OTC aspirin.
aspirin effect on thromboxane synthesis?
one dose of oral aspirin almost completely suppresses the biosynthesis of thromboxane within one hour (non-aspirin, non-acetylated salicylates do not have this effect)
Aspirin vs traditional NSAIDS?
both alter aggregation of platelets, but NSAIDs have limited effects that disappear after 1-3 days. (similar effect, but NSAIDs not as much and reversible)
ibuprofen and aspirin together?
ibuprofen impairs the effect of aspirin by blocking its access to the TXA2 receptor. Reduces aspirins cardioprotective effect and may worsen cardiovascular risk if taken together.
COX-2 inhibitors and platelets?
COX-2 inhibitors (like Celebrex) don’t affect platelets.
reasons why people take aspirin?
mostly to prevent heart attack and stroke, but 20% also list cancer prevention as reason
____% of surveyed adults report using aspirin regularly?
50%
Low dose aspiring as secondary prevention reduces all-cause mortality by ____% and subsequent MIs by ____% in people with CVD.
18% and 30%
aspirin as primary prevention for MIs?
controversial.
effective dose of aspirin
10-325mg daily. Usually 1mg/kg/day, so ~81mg (“low dose” aspirin) closest dose.
twice daily dosing and aspirin?
no advantage to twice daily dosing
risks associated with increased doses of aspirin?
GI bleed
taking aspirin @ what time of day might reduce acute cardiac events?
bedtime
why should you use caution when giving aspirin to babies, children, adolescents?
it’s been linked to Reye’s syndrome (swelling @ liver, brain)
what’s recommended for secondary prevention of stroke?
mono therapy of aspirin (50-325mg/daily)
combination therapy of aspirin (25mg) and XR dipyridamole/Aggrenox (200mg 2x/daily
mono therapy of clopidrogrel/Plavix (75mg/daily)
when deciding whether or not to use aspirin for primary prevention of heart attack or stroke, what parameter should you use?
age.
generally low dose aspirin for men 45-79 and women 55-79. Only for those 80 if have no risk for GI bleed.
what should you give in combination with aspirin to a pt with GI risks who requires aspirin therapy?
PPI
recommendations for avoiding local effects during aspirin administration?
give regular aspirin with food or use enteric coated to avoid/reduce stomach irritation
aspirin and cancer?
aspirin can help prevent colorectal cancer
what happens when you rapidly stop taking aspirin?
cessation of aspirin can cause platelet rebound phenomenon and pro-thrombotic state leading to major adverse cardiovascular events
aspirin before surgery
traditionally has been discontinued 7-10 days before surgery, but meta-analysis suggests this increases thrombo-embolitic risks and the practice should be discontinued
NSAIDs and platelet function
all NSAIDs work in varying degrees to inhibit platelet function and prolong bleeding time. All (except aspirin) reversible when drug cleared (1-3 days).
ibuprofen an aspirin together?
ibuprofen interferes with the cardio-protective and anti-platelet effects of aspirin. if take together, take aspirin 2 hours before ibuprofen. Acetaminophen, diclofenac, COX-2 inhibitors better than ibuprofen with aspirin.
P2Y12 receptor
receptor for ADP
Theinopyridine anti-platelet drugs are used for?
prevention of coronary stent thrombosis in pts undergoing percutaneous coronary intervention with stent placement